Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Frequently asked questions
What sector does Cingulate Inc. Warrants (CINGW) operate in?
Cingulate Inc. Warrants belongs to the Healthcare sector and operates in the industry.
What is Cingulate Inc. Warrants (CINGW) current stock price?
As of the latest data, Cingulate Inc. Warrants stock price is $0.01, with a previous close of $0.01. Cingulate Inc. Warrants gained $0.00 in the last trading session, representing a 15.19% increase.
What is Cingulate Inc. Warrants (CINGW) current market capitalization?
Cingulate Inc. Warrants market cap is approximately 49.42 thousand.
What is Cingulate Inc. Warrants (CINGW) Earnings Per Share (EPS)?
The trailing EPS is -$1.73.
What is Cingulate Inc. Warrants (CINGW) EBITDA?
Cingulate Inc. Warrants EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -7.80 million.
Does Cingulate Inc. Warrants (CINGW) pay dividends?
No. Cingulate Inc. Warrants does not pay a dividend.
What is Cingulate Inc. Warrants (CINGW) beta (volatility) score?
Cingulate Inc. Warrants has a beta of -0.906, indicating lower volatility than the overall market.
